New Bill Ends Free Pricing

BMI View: The requirement of drug companies and health insurers to negotiate prices of new drugs based on cost-effectiveness criteria signifies the end of the free drug pricing regime in Germany, restricting revenue earning opportunities in the third largest drug market in the world.

To read the full article, please choose one of the following options: